Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. - Investor Relations & Filings

Listed IPO Apr 2021
Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 513 across all filing types
Latest filing 2026-04-28 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688468 · 1 venue

Key figures FY2025

Period ended 2025-12-31 · CNY
Headline annual figures for CHEMCLIN DIAGNOSTICS CO., LTD., fiscal year 2025, reported in CNY, with the source filing for each figure.
Total Revenues CNY 332.68M per the Annual Report filed 2026-04-28
Net Income CNY 43.91M per the Annual Report filed 2026-04-28
Total Assets CNY 1.76B per the Annual Report filed 2026-04-28
Total Equity CNY 1.41B per the Annual Report filed 2026-04-28
Cash from Ops CNY 93.90M per the Annual Report filed 2026-04-28

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司2025年年度报告
Annual Report Classification · 100% confidence The document is titled "科美诊断技术股份有限公司2025年年度报告" which translates to "Chemclin Diagnostics Co., Ltd. 2025 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, business model, industry analysis, and audited financial statements. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes sections typical of an annual report such as financial highlights, management discussion and analysis, corporate governance, and audit opinions. The presence of audited financial statements and comprehensive company information confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2025. Therefore, the document is classified as an Annual Report (10-K). FY 2025
2026-04-28 Chinese
科美诊断技术股份有限公司独立董事2025年度述职报告（孟召伟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for a company, detailing the independent director's duties, attendance at meetings, communication with auditors, and evaluation of company governance and financial reporting compliance during the year 2025. It includes information about board composition, committee meetings, appointment of auditors and financial officers, and overall evaluation of the director's role. The document is a detailed report on the independent director's activities and responsibilities over the year, not a general annual report or financial statement. It focuses on board/management information, specifically the independent director's role and activities, which aligns with the category of Board/Management Information (MANG). The document length is 4580 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the best classification is MANG with high confidence.
2026-04-28 Chinese
科美诊断技术股份有限公司董事及高级管理人员薪酬管理制度（2026年4月）
Remuneration Information Classification · 95% confidence The document is titled '董事及高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management' of 科美诊断技术股份有限公司. It details the principles, structure, assessment, and payment of remuneration for directors and senior management, including fixed and performance-based pay, incentives, and conditions for reduction or recovery of pay. It is a policy or system document about executive compensation rather than a report of actual compensation paid or a proxy statement. It does not contain financial results or voting information. Therefore, it fits the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-04-28 Chinese
科美诊断技术股份有限公司董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the external audit firm (Rongcheng CPA Firm) for the company's 2025 annual financial report audit. It details the audit firm's qualifications, audit procedures, communication with management, and the committee's oversight activities. The document does not contain the actual audited financial statements or the audit report itself but rather discusses the audit firm's performance and the committee's supervisory role. This fits the definition of an Audit Report / Information (AR) as it is a standalone report about the audit process and oversight, not the full annual report or the audit report itself. The document length is 1817 characters, which is relatively short but contains substantive content about audit supervision, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-04-28 Chinese
科美诊断技术股份有限公司关于自愿披露公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate for a diagnostic product by a subsidiary. It details the product, its intended use, and the potential impact on the company. The document is short (1810 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous official announcements that do not fit other specific categories.
2026-04-19 Chinese
科美诊断技术股份有限公司2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025年度业绩快报公告" which translates to "2025 Annual Performance Express Report Announcement" or "Earnings Quick Report." It contains preliminary financial data for the year 2025, including revenue, profit, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the formal annual report. The document is relatively short (1812 characters) and serves as an initial announcement of financial results rather than a full detailed report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is ER with high confidence. FY 2025
2026-02-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.